Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
about
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsPersistent androgen receptor addiction in castration-resistant prostate cancerThe roles of stem cell memory T cells in hematological malignanciesBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaAutophagy in airway diseases: a new frontier in human asthma?Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHLA critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyInhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceDifferential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagyTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaBJ-1108, a 6-Amino-2,4,5-Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth through PI3K/NOX PathwayPten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasTransmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialBKM120 induces apoptosis and inhibits tumor growth in medulloblastomaA framework for genomic biomarker actionability and its use in clinical decision makingNovel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerAlpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathwayA chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer.All-trans retinoic acid arrests cell cycle in leukemic bone marrow stromal cells by increasing intercellular communication through connexin 43-mediated gap junction.Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RCSomatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4ADose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.Ibrutinib for B cell malignancies.Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapyPhosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.Novel ALK inhibitors in clinical use and development.Current and future molecular diagnostics in non-small-cell lung cancer.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
P2860
Q26766292-F5B9F118-FEC2-4038-AD5F-BB0A35CEBDF0Q26777163-B08631D4-54CD-4254-AD0D-FB8D01136578Q26783681-706E9CC6-F13C-4E17-87A0-8DC484DA6C1CQ26785828-E531D8EC-6E62-4188-B91F-EA0AB0C725B7Q26786115-165BAFD3-2161-4D6C-9ABD-722A36DCD1A2Q26795504-5D1788EB-64A9-4F1B-9D1C-6960E2426C1CQ26849503-27AAE79A-18C5-484B-BC30-0CA5206B65DDQ26991637-5AD50AA9-2EC0-4AC7-A814-A6BA555C8888Q28081735-AF01CE99-CFA8-4EF0-BE7F-5E95C3746E0AQ28087378-EE95BED3-4A5C-42BC-B472-476DD9E4BF49Q28552988-77513EA8-C122-4109-8E65-E723AA3E4B24Q28602310-5434A2D3-B877-4DBE-99DA-892A4FDFD5FEQ30787310-F2D67F6B-572C-47F6-AE8B-A3FD1CDE47EBQ31106994-FA218D7A-76FD-498C-9F68-5E98FB1D3ADCQ33431267-5E63979F-0566-4B69-99A6-56E50D862927Q33853264-90E78981-FF5E-4867-A591-CF441D3F44CDQ34781122-0C5B8E52-A13F-4F24-B953-5897F9413536Q35072441-17743280-54E8-45D5-B41A-B07C6F87A332Q35177876-C7B4BC46-F578-44CD-8C0A-EB90106EC787Q35380714-438E9DFF-D613-44B1-8EA2-016E9E7CD721Q35604577-8045C19D-992A-4C9A-B1C4-16AEBF2D682AQ35640503-CE3E4849-305B-4DBB-8A4D-37FC9211CE03Q35945939-8CA56FCB-FEF0-4427-AB21-8B8B588F07C5Q36134845-5E505D1C-8E15-46B6-8FEE-74638553AC76Q36232304-363C6AD5-7C56-4000-8E9C-FEC94EB56540Q36260672-9F80680C-911D-4F74-8124-FC7C6340A7BFQ36416861-DB06FA8D-6BBC-473E-8DA9-802500B9BB30Q37128293-E1B75F1A-A2A5-4A8F-8FF0-7D3541B8D942Q37555418-19EB70CE-090B-43F8-9B79-C1190D56CCD4Q37583378-518F960A-93C8-4A36-86D2-B6D59B4CE056Q37620907-D8E61448-7741-431A-B3F0-23F64868BD22Q37696147-BAC00DFA-F59B-46FF-B03E-261C875141D8Q38193084-BDCF2895-C164-4922-8E9D-9D5CA66DFED1Q38260357-0E35E445-29DB-414E-857E-E805D7A9CA02Q38364936-9867FA09-76EF-493F-9156-B3DA24E1AC41Q38375141-567F2AD1-6FCA-420E-8295-D440F22AC7DBQ38427240-E5F0924A-C529-4690-885A-6A1FA2163310Q38543780-0EA4476F-D57E-4A3F-A395-1C06E28C8A4EQ38544216-7AE49CC1-EF52-4CBB-B708-0DB8CE874701Q38558611-2AA890ED-E67A-4293-8FF4-11662EC6D6DC
P2860
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
@en
type
label
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
@en
prefLabel
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
@en
P2093
P2860
P921
P356
P1476
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
@en
P2093
Akintunde Akinleye
Delong Liu
Parthu Avvaru
Yongping Song
P2860
P2888
P356
10.1186/1756-8722-6-88
P5008
P577
2013-11-22T00:00:00Z
P5875
P6179
1034705764